[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0816134A2 - Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. - Google Patents

Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.

Info

Publication number
BRPI0816134A2
BRPI0816134A2 BRPI0816134-8A BRPI0816134A BRPI0816134A2 BR PI0816134 A2 BRPI0816134 A2 BR PI0816134A2 BR PI0816134 A BRPI0816134 A BR PI0816134A BR PI0816134 A2 BRPI0816134 A2 BR PI0816134A2
Authority
BR
Brazil
Prior art keywords
herpesvirus
infectious particles
vector
treatment
dna sequence
Prior art date
Application number
BRPI0816134-8A
Other languages
English (en)
Inventor
Bérénice COSTES
François LIEFFRIG
Alain Vanderplasschen
Original Assignee
Université de Liège
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07115093A external-priority patent/EP2031065A1/en
Application filed by Université de Liège filed Critical Université de Liège
Publication of BRPI0816134A2 publication Critical patent/BRPI0816134A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0816134-8A 2007-08-28 2008-08-26 Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. BRPI0816134A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07115093A EP2031065A1 (en) 2007-08-28 2007-08-28 A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyprinus carpio carpio or Cyprinus carpio koi
EP07120939 2007-11-16
PCT/EP2008/061168 WO2009027412A1 (en) 2007-08-28 2008-08-26 A recombinant koi herpesvirus (khv) or cyprinid herpesvirus 3 (cyhv-3) and a vaccine for the prevention of a disease caused by khv/cyhv-3 in cyprinus carpio carpio or cyprinus carpio koi

Publications (1)

Publication Number Publication Date
BRPI0816134A2 true BRPI0816134A2 (pt) 2015-07-28

Family

ID=40020044

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816134-8A BRPI0816134A2 (pt) 2007-08-28 2008-08-26 Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.

Country Status (12)

Country Link
US (1) US20110287050A1 (pt)
EP (1) EP2195021B1 (pt)
JP (1) JP2010536394A (pt)
CN (1) CN101820905A (pt)
AT (1) ATE547118T1 (pt)
BR (1) BRPI0816134A2 (pt)
MD (1) MD20100029A (pt)
MX (1) MX2010002122A (pt)
RS (1) RS20100059A (pt)
RU (1) RU2010111725A (pt)
TW (1) TW200924792A (pt)
WO (1) WO2009027412A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120135422A1 (en) * 2009-03-31 2012-05-31 Mie University Anti-gpcr antibody and the method of producing the same
EP2487241A1 (en) 2011-02-09 2012-08-15 Westfälische Wilhelms-Universität Münster RNAi agents and compositions useful as carp therapeutics
PL2797627T3 (pl) 2011-12-30 2021-06-28 Gesval S.A. Rekombinowany herpeswirus Koi (KHV) oraz szczepionka do zapobiegania chorobie wywołanej przez KHV
CN102973951A (zh) * 2012-11-26 2013-03-20 吉林农业大学 一种锦鲤疱疹病毒orf25核酸疫苗
CN104031143A (zh) * 2013-07-02 2014-09-10 广东省农业科学院动物卫生研究所 一种抗鲤科疱疹病毒3型鸡卵黄抗体及其制备方法和应用
CA2974868A1 (en) * 2015-02-11 2016-08-18 Alma Mater Studiorum Universita' Di Bologna Retargeted herpesvirus with a glycoprotein h fusion
CN105755014B (zh) * 2016-03-23 2019-03-19 中国科学院水生生物研究所 CaHV-TNFR特异基因及应用
CN106834352B (zh) * 2017-02-27 2020-06-16 苏州大学 基于杆状病毒表达系统制备包裹鲤疱疹病毒ii型抗原的多角体的方法
CN109294974B (zh) * 2018-10-22 2022-09-13 浙江省淡水水产研究所 一种异育银鲫脊髓组织细胞系及其构建方法与其应用
CN112279896B (zh) * 2018-11-05 2022-06-21 共鳞实业(深圳)有限公司 一种用于鱼类预防或治疗CyHV-2感染的试剂及应用
CN110423714B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种乳酸菌复合菌剂及其在抗鲤疱疹病毒ii型中的应用
CN113068640A (zh) * 2021-03-19 2021-07-06 北京市水产科学研究所（国家淡水渔业工程技术研究中心） 一种红色皮肤高覆盖率锦鲤品系的选育方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
JPH09267A (ja) * 1995-06-23 1997-01-07 Kyoritsu Shoji Kk チミジンキナーゼ遺伝子に変異を有する組換えネコヘルペスウイルス１型及びそれを含むワクチン
NZ512302A (en) 1998-12-21 2003-08-29 Akzo Nobel Nv Method to produce inactivated w/o emulsion adjuvated vaccines
IL153775A0 (en) 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection

Also Published As

Publication number Publication date
EP2195021B1 (en) 2012-02-29
US20110287050A1 (en) 2011-11-24
TW200924792A (en) 2009-06-16
MD20100029A2 (ro) 2010-08-31
CN101820905A (zh) 2010-09-01
RS20100059A (en) 2011-06-30
EP2195021A1 (en) 2010-06-16
ATE547118T1 (de) 2012-03-15
MX2010002122A (es) 2010-07-06
WO2009027412A1 (en) 2009-03-05
JP2010536394A (ja) 2010-12-02
RU2010111725A (ru) 2011-10-10
MD20100029A (ro) 2010-08-31

Similar Documents

Publication Publication Date Title
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
IL189313A (en) Virus-like particles as virus-paramixo vaccines, a method for their preparation and use
HK1120730A1 (en) Nipah virus vaccines nipah
TR201908199T4 (tr) HPV'ye karşı aşılar.
BRPI1015053A2 (pt) partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
WO2006014292A3 (en) Oral vaccine for borrelia
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
WO2010014567A3 (en) Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
WO2016116905A9 (en) Cmv antigens and uses thereof
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
Sautto et al. Next generation vaccines for infectious diseases
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2007098717A3 (es) Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
MX2020006476A (es) Vacuna contra el virus de lassa.
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
MX363264B (es) Vectores de vacuna recombinante de herpesvirus bovino 1 (bohv-1) con baja virulencia.
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.